10-Q Filing

SWK Holdings Corp CIK: 1089907 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001552781-20-000449`
Period End Date	20200630
Filing Date	20200814
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	swkh-20200630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 86 Cash Flow Statement 76 Stockholders Equity 33 Comprehensive Income 14

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$17.17M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$27.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$11.16M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$20.23M	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$2.55M	USD	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$2.00M	USD	Point-in-time
Marketable investments	`MarketableSecurities`	$1.80M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Marketable investments	`MarketableSecurities`	$1.31M	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.09M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$2.24M	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$22.73M	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	12.92M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$16.60M	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	12.85M	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	12.92M	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	12.85M	shares	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$178.38M	USD	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$172.82M	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$270.00K	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$466.00K	USD	Point-in-time
Deferred tax asset, net	`DeferredTaxAssetsLiabilitiesNet`	$25.53M	USD	Point-in-time
Deferred tax asset, net	`DeferredTaxAssetsLiabilitiesNet`	$25.78M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$3.56M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$2.34M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$25.11M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$18.52M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$1.29M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$2.59M	USD	Point-in-time
Other non-current assets	`PrepaidExpenseAndOtherAssets`	$336.00K	USD	Point-in-time
Other non-current assets	`PrepaidExpenseAndOtherAssets`	$242.00K	USD	Point-in-time
Total assets	`Assets`	$254.37M	USD	Point-in-time
Total assets	`Assets`	$259.01M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.06M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.92M	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	-	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	$6.45M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.36M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.06M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$16.29M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$14.50M	USD	Point-in-time
Warrant liability	`WarrantsAndRightsOutstanding`	$76.00K	USD	Point-in-time
Warrant liability	`WarrantsAndRightsOutstanding`	$101.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$203.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$1.17M	USD	Point-in-time
Total liabilities	`Liabilities`	$26.93M	USD	Point-in-time
Total liabilities	`Liabilities`	$17.84M	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,849,238 and 12,917,348 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$13.00K	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,849,238 and 12,917,348 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$13.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.20B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.20B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$223.34M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$232.08M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$213.06M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$236.53M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$218.97M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$232.00M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$254.37M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$259.01M	USD	Point-in-time

Income Statement 86 line items

Line Item	Tag	Value	Unit	Period
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$7.73M	USD	1 Quarter
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$14.87M	USD	2 Qtrs
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$15.04M	USD	2 Qtrs
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$5.65M	USD	1 Quarter
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$150.00K	USD	1 Quarter
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$298.00K	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	-	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	-	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$1.00K	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$20.00K	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$38.00K	USD	2 Qtrs
Other	`RevenueNotFromContractWithCustomerOther`	$2.00K	USD	2 Qtrs
Total revenues	`Revenues`	$15.05M	USD	2 Qtrs
Total revenues	`Revenues`	$15.21M	USD	2 Qtrs
Total revenues	`Revenues`	$7.90M	USD	1 Quarter
Total revenues	`Revenues`	$5.66M	USD	1 Quarter
Provision for credit losses	`ProvisionForLoanAndLeaseLosses`	-	USD	1 Quarter
Provision for credit losses	`ProvisionForLoanAndLeaseLosses`	$609.00K	USD	2 Qtrs
Provision for credit losses	`ProvisionForLoanAndLeaseLosses`	-	USD	2 Qtrs
Provision for credit losses	`ProvisionForLoanAndLeaseLosses`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	$163.00K	USD	2 Qtrs
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	2 Qtrs
Interest expense	`InterestExpense`	$163.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$264.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$180.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$78.00K	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$2.16M	USD	2 Qtrs
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	-	USD	2 Qtrs
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	-	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$1.01M	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$5.00K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationAndAmortization`	$6.95M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$9.00K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$3.44M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.32M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.69M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.65M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.58M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$17.01M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$9.05M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$3.38M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$1.40M	USD	1 Quarter
Unrealized net gain (loss) on warrants	`UnrealizedNetLossGainOnWarrants`	$622.00K	USD	1 Quarter
Unrealized net gain (loss) on warrants	`UnrealizedNetLossGainOnWarrants`	$748.00K	USD	1 Quarter
Unrealized net gain (loss) on warrants	`UnrealizedNetLossGainOnWarrants`	$1.01M	USD	2 Qtrs
Unrealized net gain (loss) on warrants	`UnrealizedNetLossGainOnWarrants`	$-1.24M	USD	2 Qtrs
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-488.00K	USD	2 Qtrs
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$402.00K	USD	1 Quarter
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	2 Qtrs
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	1 Quarter
(Loss) income before provision (benefit) for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$12.67M	USD	2 Qtrs
(Loss) income before provision (benefit) for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-125.00K	USD	1 Quarter
(Loss) income before provision (benefit) for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-3.53M	USD	2 Qtrs
(Loss) income before provision (benefit) for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$5.00M	USD	1 Quarter
(Benefit) provision for income taxes	`IncomeTaxExpenseBenefit`	$252.00K	USD	2 Qtrs
(Benefit) provision for income taxes	`IncomeTaxExpenseBenefit`	$674.00K	USD	1 Quarter
(Benefit) provision for income taxes	`IncomeTaxExpenseBenefit`	$-1.00M	USD	1 Quarter
(Benefit) provision for income taxes	`IncomeTaxExpenseBenefit`	$1.78M	USD	2 Qtrs
Consolidated net (loss) income	`ProfitLoss`	$6.56M	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$876.00K	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Consolidated net (loss) income	`ProfitLoss`	$-4.66M	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$4.33M	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$10.89M	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.34	USD	1 Quarter
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.84	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$-0.29	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.07	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.34	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.07	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.29	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.84	USD	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	12.90M	shares	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	12.90M	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	12.91M	shares	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	12.90M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.90M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.91M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.91M	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.91M	shares	2 Qtrs

Cash Flow Statement 76 line items

Line Item	Tag	Value	Unit	Period
Consolidated net (loss) income	`ProfitLoss`	$6.56M	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$876.00K	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Consolidated net (loss) income	`ProfitLoss`	$-4.66M	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$4.33M	USD	1 Quarter
Consolidated net (loss) income	`ProfitLoss`	$10.89M	USD	2 Qtrs
Provision for loan credit losses	`ProvisionForLoanAndLeaseLosses`	-	USD	1 Quarter
Provision for loan credit losses	`ProvisionForLoanAndLeaseLosses`	$609.00K	USD	2 Qtrs
Provision for loan credit losses	`ProvisionForLoanAndLeaseLosses`	-	USD	2 Qtrs
Provision for loan credit losses	`ProvisionForLoanAndLeaseLosses`	-	USD	1 Quarter
Impairment expense	`AssetImpairmentCharges`	-	USD	2 Qtrs
Impairment expense	`AssetImpairmentCharges`	$163.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$94.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$93.00K	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$1.78M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$252.00K	USD	2 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$-1.01M	USD	2 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$1.24M	USD	2 Qtrs
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-488.00K	USD	2 Qtrs
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$402.00K	USD	1 Quarter
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	2 Qtrs
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	2 Qtrs
Loan discount amortization and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$965.00K	USD	2 Qtrs
Loan discount amortization and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$-483.00K	USD	2 Qtrs
Interest paid-in-kind	`PaidInKindInterest`	$1.75M	USD	2 Qtrs
Interest paid-in-kind	`PaidInKindInterest`	$805.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$88.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$370.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$190.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$183.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$102.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Interest income in excess of cash collected	`InterestIncomeInExcessOfCashCollected`	$-82.00K	USD	2 Qtrs
Interest income in excess of cash collected	`InterestIncomeInExcessOfCashCollected`	-	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAmortizationAndAccretionNet`	$6.95M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAmortizationAndAccretionNet`	$9.00K	USD	2 Qtrs
Interest and accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$16.00K	USD	2 Qtrs
Interest and accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$553.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherCurrentAssets`	$-29.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherCurrentAssets`	$-1.16M	USD	2 Qtrs
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.29M	USD	2 Qtrs
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$889.00K	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$10.86M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.13M	USD	2 Qtrs
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$6.11M	USD	2 Qtrs
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$33.54M	USD	2 Qtrs
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$3.26M	USD	2 Qtrs
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$30.59M	USD	2 Qtrs
Corporate debt security principal payment	`MarketableInvestmentPrincipalPayment`	$33.00K	USD	2 Qtrs
Corporate debt security principal payment	`MarketableInvestmentPrincipalPayment`	$34.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.49M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$172.00K	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.92M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.47M	USD	2 Qtrs
Net proceeds from credit facility	`ProceedsFromRepaymentsOfLinesOfCredit`	-	USD	2 Qtrs
Net proceeds from credit facility	`ProceedsFromRepaymentsOfLinesOfCredit`	$6.45M	USD	2 Qtrs
Repurchases of common stock, including fees and expenses	`PaymentsForRepurchaseOfCommonStock`	$1.09M	USD	2 Qtrs
Repurchases of common stock, including fees and expenses	`PaymentsForRepurchaseOfCommonStock`	$798.00K	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-798.00K	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.35M	USD	2 Qtrs
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$6.01M	USD	2 Qtrs
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$7.15M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$17.17M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$27.37M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$11.16M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$20.23M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$17.17M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$27.37M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$11.16M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$20.23M	USD	Point-in-time

Stockholders Equity 33 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$223.34M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$232.08M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$213.06M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$236.53M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$218.97M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$232.00M	USD	Point-in-time
Stock-based compensation	`ShareBasedCompensation`	$88.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$370.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$190.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$183.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$102.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Issuance of common stock in lieu of payment of employee cash bonuses	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$60.00K	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Repurchases of common stock in open market	`StockRepurchasedDuringPeriodValue`	$53.00K	USD	1 Quarter
Repurchases of common stock in open market	`StockRepurchasedDuringPeriodValue`	$62.00K	USD	1 Quarter
Repurchases of common stock in open market	`StockRepurchasedDuringPeriodValue`	$1.03M	USD	1 Quarter
Repurchases of common stock in open market	`StockRepurchasedDuringPeriodValue`	$745.00K	USD	1 Quarter
Net income	`ProfitLoss`	$6.56M	USD	1 Quarter
Net income	`ProfitLoss`	$876.00K	USD	1 Quarter
Net income	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Net income	`ProfitLoss`	$-4.66M	USD	1 Quarter
Net income	`ProfitLoss`	$4.33M	USD	1 Quarter
Net income	`ProfitLoss`	$10.89M	USD	2 Qtrs
Ending Balance	`StockholdersEquity`	$223.34M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$232.08M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$213.06M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$236.53M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$218.97M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$232.00M	USD	Point-in-time

Comprehensive Income 14 line items

Line Item	Tag	Value	Unit	Period
Consolidated net income	`ProfitLoss`	$6.56M	USD	1 Quarter
Consolidated net income	`ProfitLoss`	$876.00K	USD	1 Quarter
Consolidated net income	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Consolidated net income	`ProfitLoss`	$-4.66M	USD	1 Quarter
Consolidated net income	`ProfitLoss`	$4.33M	USD	1 Quarter
Consolidated net income	`ProfitLoss`	$10.89M	USD	2 Qtrs
Other comprehensive income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Other comprehensive income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	-	USD	2 Qtrs
Other comprehensive income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Other comprehensive income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	-	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$4.33M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$876.00K	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$-3.78M	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$10.89M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.